LOZOL
LOE ApproachingNDAORALTABLET
Approved
Jul 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 11h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOZOL is an oral tablet small-molecule drug approved in 1983 by Sanofi. The generic name and mechanism of action are not currently specified in available data, limiting identification of its therapeutic indication and patient population.
LOE Approaching
As a mature product approaching loss of exclusivity with moderate competitive pressure (30), the brand team is likely focused on lifecycle extension and managing decline rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
LOZOL currently has zero linked job postings, reflecting its mature lifecycle stage and approaching loss of exclusivity. Career opportunities on this product are limited and focused on managing decline rather than growth.
Brand ManagerField Sales
Worked on LOZOL at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.